

Acute Flaccid Quadripareisis as an Uncommon Initial Presentation of SLE: A Case Report and Literature Review

Omar Faroque^{1*}, Nourin Sultana², Abdur Rahaman³, Syed Fazlul Islam⁴, Col Iqbal Karim⁵, Muhammad Nazrul Islam⁶, A. H. Hamid Ahmed⁷

¹Associate Professor, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

²Resident of Nephrology (Phase B), Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

³Resident of Nephrology (Phase B), Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

⁴Assistant professor, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

⁵Professor, Department of Pathology, Armed Forces Institute of Pathology, RC72+H89, Shaheed Sharani, Dhaka, Bangladesh

⁶Professor, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

⁷Professor and Chairman, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

DOI: <https://doi.org/10.36347/sjmcr.2025.v13i01.012>

| Received: 16.11.2024 | Accepted: 22.12.2024 | Published: 08.01.2025

*Corresponding author: Omar Faroque

Associate Professor, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Abstract

Case Report

Systemic lupus erythematosus (SLE) is an autoimmune, multisystem disorder that has a high morbidity and mortality rate involving millions of people worldwide. It has a diverse presentation due to its ability to affect almost all body organs. Here we present a case of a 22-year-old female who presented to us with acute flaccid quadripareisis. Subsequently, there was 6th cranial nerve palsy, proximal muscle weakness, joint stiffness, and proteinuria. Laboratory investigations show positive ANA, Anti-ds-DNA, and Anti Sm Ab. She was diagnosed as a case of SLE and was treated with IV Methylprednisolone. After getting the treatment her symptoms were improved.

Keywords: Autoimmune, Multisystem, Flaccid Quadripareisis, Cranial Nerve Palsy, Autoantibodies.

Copyright © 2025 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

SLE was first described by the great physician Hippocrates (460–375 bc) as cutaneous ulcers under the heading of herpes esthiomenos. Since then it has been considered a skin disease. Sir William Osler first stated that SLE can involve other organs even without skin manifestation [1]. It is an autoimmune, inflammatory disorder that most commonly affects females of reproductive age. The main pathology is the dysfunction of the immune system. There is production of autoantibodies due to loss of B and T cell tolerance. Antibodies are mainly formed against nuclear antigens resulting in widespread inflammation and ultimately tissue injury [2]. The morbidity and mortality of SLE patients are two to three times higher than the normal population depending upon the organ involvement [3]. The reported incidence and prevalence of SLE differ significantly by geography. Age, gender, and ethnicity are the main factors in determining the clinical outcome and management. Though this disease is more prevalent in the female population, its course is more critical and devastating in men [4]. Though SLE is an incurable disease early diagnosis and proper management can

delay the progression of diseases, and major organ damage. The common presentations of SLE are skin manifestation, oral ulcer, musculoskeletal involvement, and serositis. But sometimes it may have a bizarre presentation. A high level of suspicion is necessary regarding SLE if a female of reproductive age presents with multisystem involvement. In this report, we present a case with acute onset flaccid quadripareisis along with cranial nerve palsy subsequently musculoskeletal manifestation, and renal involvement as the early presentation of SLE.

CASE HISTORY

A 22-year-old female presented to us with complaints of weakness in all four limbs for one month. Initially, she felt numbness and tingling sensation in her upper limbs, gradually spreading to her lower limbs. Two to three days later she noticed heaviness in her lower limbs with difficulties walking. There was decreased sensation in the affected limbs. She also had problems standing from sitting posture without the help of others. Fifteen days later she developed double vision mostly on the right side on the lateral gaze. During this course of

Citation: Omar Faroque, Nourin Sultana, Abdur Rahaman, Syed Fazlul Islam, Col Iqbal Karim, Muhammad Nazrul Islam, A. H. Hamid Ahmed. Acute Flaccid Quadripareisis as an Uncommon Initial Presentation of SLE: A Case Report and Literature Review. Sch J Med Case Rep, 2025 Jan 13(1): 64-68.

the disease, she gradually developed joint stiffness, especially in the morning mainly involving small joints of her hands which persisted for about 1-2 hours. She also had pain in the elbow joint and shoulder joint which was asymmetrical in distribution and inflammatory in nature. The patient also complained of extreme fatigue and myalgia. Seven days before admission she noticed decreased urine output though the urine color was normal without any dysuria or abdominal pain and gradual periorbital puffiness with bilateral leg swelling. She had no recent history of diarrhea, respiratory tract infection, vaccination, surgery, and trauma. Her father is a known

case of Psoriatic arthritis. Clinical examination revealed she was mildly anemic and edematous, her BP was 120/70 mmHg, and her pulse was 90b/min. A nervous system exam showed right 6th cranial nerve palsy, muscle tone reduced, muscle power 3/5 in lower limbs, 4/5 in the upper limbs, jerks are absent in both upper and lower limbs, plantar flexor (bilateral), coordination was impaired due to muscle weakness. A sensory exam revealed a decrease in fine touch and pain sensation. Position and vibration sense were intact. The Gower sign was positive. Other Systemic examinations revealed normal findings.

Investigations showed

CBC	Hb 10.6 gm/dl TWBC: 3200 Plt :250000 ESR :50mm in 1st hour
Urine RE	Protein :4+ Pus cell : 12-15/HPF RBC: nil Cast : nil
S. Creatinine	0.5 mg/dl
UTP	13gm/day
S albumin	2.4gm /dl
CRP	1.6mg/dl
ANA	Positive
Anti dsDNA	Positive
Anti Sm Ab	Positive
Anti uRNP	Positive
CPK	51.0U/L
C3,C4	Normal
RA, Anti CCP	Negative
APS panel	Negative
liver function test	Normal
S vitamin B12, folic acid	Normal
USG of whole abdomen	Right kidney 11.3 cm; left kidney 11.4 cm Cortical echogenicity–normal, CMD well maintained
chest Xray PA view was	Normal
CSF study	Albuminocytological dissociation
MRI of the brain with screening of the spinal cord	No abnormalities
NCS of all four limbs.	Prolonged distal latency in the right median nerve and left ulnar nerve. Reduced Camp amplitude only in the right ulnar nerve. F response was absent in both ulnar nerves and prolonged in all other nerves
Renal Biopsy	Light microscopy: focal mesangial proliferation, endocapillary hypercellularity, wire loop lesion (Figure 1) DIF: Immune deposit of IgG(1+), IgA(1+), C3(1+), Kappa(1+), Lambda(1+), C1q and IgM trace Light microscpic and DIF findings were suggestive of class III of lupus nephritis




Figure 1: Mesangial proliferative changes and wire loop lesion (right) in renal biopsy

IBN SINA DIAGNOSTIC & CONSULTATION CENTER, CHATTOGRAM Neurology Department															
Patient Information					In/Out Patient										
Name		Miss Ramisa			Referral Dept		Neurology								
Date of Birth		23/			Physician		Prof Hassanuzzaman								
Age		23			Examination Date		30/11/2024								
Sex		Female			Examination No										
Urgent					Examined by										
Device															
ID: 17100013															
Motor Nerve Conduction Study															
Site	Latency (ms)	Amplitude	Area	Segment	Conduction time (ms)	Interval (ms)	NCV (m/s)	NCV N.D.							
Median L															
Wrist	4.22ms	8.34mV	26.92mVms	Wrist		4.22ms									
Elbow	8.52ms	9.66mV	27.66mVms	Wrist - Elbow	220mm	4.30ms	51.2m/s								
Ulnar L															
Wrist	3.44ms	6.99mV	21.47mVms	Wrist		3.40ms									
Elbow	7.44ms	6.14mV	20.11mVms	Wrist - Elbow	260mm	3.94ms	64.4m/s								
Axilla	9.24ms	6.10mV	19.78mVms	Elbow - Axilla	110mm	1.82ms	60.4m/s								
Median R															
Wrist	4.98ms	12.89mV	38.65mVms	Wrist		4.98ms									
Elbow	9.36ms	12.14mV	36.94mVms	Wrist - Elbow	240mm	4.38ms	54.8m/s								
Ulnar R															
Wrist	3.2ms	4.42mV	21.21mVms	Wrist		3.20ms									
Elbow	7.9ms	4.47mV	17.89mVms	Wrist - Elbow	260mm	4.70ms	55.3m/s								
Axilla	9.32ms	4.40mV	17.72mVms	Elbow - Axilla	110mm	1.42ms	77.5m/s								
Tibial L															
Ankle	3.7ms	11.07mV	26.23mVms	Ankle		3.70ms									
Popliteal	12.5ms	8.01mV	27.68mVms	Ankle - Popliteal	400mm	8.80ms	45.5m/s								
Peroneal L															
Ankle	4.5ms	5.74mV	18.93mVms	Ankle		5.20ms									
Head of fibula	13.2ms	2.62mV	8.05mVms	Ankle - Head of fibula	310mm	6.00ms	51.7m/s								
Popliteal	12.7ms	2.88mV	9.29mVms	Head of fibula - Popliteal	90mm	1.42ms	60.0m/s								
Tibial R															
Ankle	5.15ms	9.39mV	25.16mVms	Ankle		5.45ms									
Popliteal	13.15ms	6.16mV	19.88mVms	Ankle - Popliteal	400mm	7.70ms	51.9m/s								
Peroneal R															
Ankle	5.2ms	5.12mV	16.60mVms	Ankle		5.20ms									
Head of fibula	11.8ms	4.12mV	14.15mVms	Ankle - Head of fibula	310mm	6.60ms	47.0m/s								
Popliteal	13.65ms	4.25mV	15.43mVms	Head of fibula - Popliteal	90mm	1.85ms	48.6m/s								
F-wave Study															
Nerve	Stim Site	F-Lat	F-Lat N.D.	M Lat	F-M Lat	F Occur	Distance	FWCV	N.D.						
Median L	Wrist	35.1ms		3.55ms	30.55ms	33 (100%)									
Ulnar L	Wrist	00				0 (0.0%)									
Median R	Wrist	36.85ms		4.7ms	32.15ms	0 (1.0%)									
Ulnar R	Wrist	00				0 (0.0%)									
Tibial L	Ankle	65.6ms				0 (0.0%)									
Tibial R	Ankle	71ms		5.1ms	65.9ms	2 (2.0%)									
Sensory Nerve Conduction Study															
Site	Latency (ms)	Amplitude	Area	Segment	Conduction time (ms)	Interval (ms)	NCV (m/s)	NCV N.D.							
Median L															
Wrist	2.44ms	65.80uV	5.05uVms	Wrist		2.44ms									
Ulnar L															
Wrist	2.02ms	49.10uV	4.24uVms	Wrist		2.02ms									

Median R									
Wrist	2.5ms	55.60uV	3.82uVms	Wrist					
Ulnar R									
Wrist	2.18ms	68.60uV	4.04uVms	Wrist					
Sural L									
Sural	2.74ms	8.85uV	0.49uVms	Sural					
Sural R									
Sural	2.92ms	6.72uV	0.51uVms	Sural					
Impression									
NCS of all four limbs are done.									
FINDINGS: Motor NCS reveals slightly prolonged DL in right median & left ulnar nerves with reduced CMAP amplitudes only in right ulnar nerve.									
F-responses are absent in both ulnar nerves and prolonged in all other studied nerves.									
Sensory NCS findings are within normal limit.									
IMPRESSION: These electrophysiological findings are consistent mostly with polyradiculopathy.									
NB Please correlate clinically (? Early features of GBS).									
Date: 8/13/2024									
Signature: Dr. Akramul Azam									
Dr. Akramul Azam MBBS, MD (Neurology) Trained in NCS & EMG (NCS) Assistant Professor (Neurology) Chittagong Medical College									

Figure 2: NCS of all four limbs

After clinical and laboratory evaluation the patient was diagnosed as a case of SLE with lupus nephritis with AIDP. She was treated with IV methylprednisolone. After getting treatment her 6th nerve palsy improved, and muscle power became 5/5 in the upper limb and 4/5 in the lower limbs. Sensory abnormalities resolved. UTP decreased to 3 gm/day, leukopenia improved (TWBC 9000), and proximal myopathy partially improved. She was put on oral

prednisolone 0.5mg/kg/day and Tab Mycophenolate Mofetil 2gm/day.

DISCUSSION

Study shows that in Bangladesh Fever (71.0%), joint pain (60.0%), and alopecia (28.0%) are the most common initial presentations. Constitutional symptoms such as fatigue, malaise and weakness (23.5%), malar rash (21.0%), oral ulcer (20.0%), photosensitivity

(15.0%), and Raynaud's phenomenon (13.0%) are also present in variable proportions [5]. The prevalence of Neuropsychiatric lupus (NPSLE) in SLE patients is 30-40% [6].

NPSLE means neurological and psychiatric disorders. It has a high heterogeneity of clinical phenotypes, including headaches, psychiatric symptoms, and peripheral neuropathy [7]. The symptoms of NPSLE have been classified into 19 neuropsychiatric (NP) manifestations by the American College of Rheumatology (ACR). These manifestations are again classified into two major divisions based on the involvement of central and peripheral nervous systems. Among the peripheral nervous system involvement Guillain-Barre syndrome, autonomic dysfunction, mononeuropathy, polyneuropathy, myasthenia gravis, and cranial nerve palsy are reported [8]. Among the autoantibodies Anti-Sm antibodies (anti-Sm) and anti-U1-ribonucleoprotein antibodies (anti-RNP) are frequently found in patients with NPSLE [7]. Anti-Sm recognizes the U1, U2, U4/U6 and U5 small nuclear RNPs (snRNPs), and anti-RNP recognizes the U1snRNPs [8, 9]. The presence of serum anti-Sm is associated with the prevalence of diffuse NPSLE [10], and high mortality in NPSLE [11]. High anti-RNP levels were also found in patients with NPSLE in both serum and cerebrospinal fluid [12]. Matsueda *et al.*, showed that anti-Sm and anti-RNP bind on the cell surface of monocytes and synergistically enhance the production of IL-6 by human monocytes causing axonal degeneration, demyelination [13] the incidence of SLE in patients with GBS is less common about 0.6% to 1.7% [14]. Initial presentation as AIDP or cranial nerve involvement is very rare. It is uncertain whether the pathogenic mechanism of SLE is inflammatory, thrombotic, or mixed. The most widely accepted pathogenesis is antibody-mediated neuronal involvement, which causes vasculopathy, intrathecal production of proinflammatory cytokines, and accelerated atherosclerosis [15]. In our case patient had both AIDP and 6th cranial nerve palsy both are very rare manifestations. Gradually there was involvement of the musculoskeletal system and kidney. Anti-Sm antibody is associated both with peripheral nerve involvement and renal involvement and it is positive in our patient. Immunosuppressive therapy like high-dose steroids, Cyclophosphamide, Mycophenolate Mofetil, and antimalarial drugs can be used to treat this condition. Rituximab is also a very good option. In our case, we treated the patient with high-dose steroids and MMF. Cyclophosphamide was refused by the patient due to fertility issues. After getting treatment with IV methylprednisolone patient was improved evidenced by improvement of muscle power and resolution of 6th nerve palsy, reduction of proteinuria.

CONCLUSION

SLE is a disease with diverse presentation. Initial presentation may be with widespread organ

damage. Early initiation of immunosuppressive may be life-saving for this patient as every hour matters in this case. For early initiation of therapy, early diagnosis is mandatory. So high level of clinical suspicion is necessary when a young female presents with multi-organ involvement within a very short period.

REFERENCE

1. Smith, C. D., & Cyr, M. (1988). The history of lupus erythematosus: from Hippocrates to Osler. *Rheumatic Disease Clinics of North America*, 14(1), 1-14.
2. Cuchacovich, R., & Gedalia, A. (2009). Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. *Rheumatic Disease Clinics*, 35(1), 75-93.
3. Barber, M. R., Drenkard, C., Falasinnu, T., Hoi, A., Mak, A., Kow, N. Y., ... & Ramsey-Goldman, R. (2021). Global epidemiology of systemic lupus erythematosus. *Nature Reviews Rheumatology*, 17(9), 515-532.
4. Ameer, M. A., Chaudhry, H., Mushtaq, J., Khan, O. S., Babar, M., Hashim, T., ... & Hashim, S. (2022). An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. *Cureus*, 14(10).
5. Ahmmad, A. M., Yeasmin, S., Islam, M. N., Akter, M. S., & Islam, M. S. (2022). Pattern of Initial Clinical Presentation of Systemic Lupus Erythematosus: A Hospital-Based Cross-Sectional Study from Bangladesh. *Mymensingh Medical Journal: MMJ*, 31(3), 812-818.
6. Sanna, G., Bertolaccini, M. L., Cuadrado, M. J., Laing, H., Khamashta, M. A., Mathieu, A., & Hughes, G. R. (2003). Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. *The Journal of rheumatology*, 30(5), 985-992.
7. Fujieda, Y. (2020). Diversity of neuropsychiatric manifestations in systemic lupus erythematosus. *Immunological medicine*, 43(4), 135-141.
8. Liang, M. H., Corzillius, M., Bae, S. C., Lew, R. A., Fortin, P. R., Gordon, C., ... & Winer, J. B. (1999). The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis and rheumatism*, 42(4), 599-608.
9. Tan, E. M. (1989). Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. *Advances in immunology*, 44, 93-151.
10. Tikly, M., Burgin, S., Mohanlal, P., Bellingan, A., & George, J. (1996). Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. *Clinical rheumatology*, 15, 143-147.

11. Abe, G., Kikuchi, H., Arinuma, Y., & Hirohata, S. (2017). Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. *Modern rheumatology*, 27(2), 278-283.
12. Sato, T., Fujii, T., Yokoyama, T., Fujita, Y., Imura, Y., Yukawa, N., ... & Mimori, T. (2010). Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. *Arthritis & Rheumatism*, 62(12), 3730-3740.
13. Matsueda, Y., Arinuma, Y., Nagai, T., & Hirohata, S. (2018). Synergistic enhancement of production of proinflammatory cytokines of human peripheral blood monocytes by anti-Sm and anti-RNP antibodies. *Plos one*, 13(12), e0209282.
14. Korn-Lubetzki, I., & Abramsky, O. (1986). Acute and chronic demyelinating inflammatory polyradiculoneuropathy: association with autoimmune diseases and lymphocyte response to human neuritogenic protein. *Archives of neurology*, 43(6), 604-608.
15. Bertsias, G. K., & Boumpas, D. T. (2010). Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. *Nature Reviews Rheumatology*, 6(6), 358-367.